least 1 year ago) presenting to our outpatient nephrology clinic for follow-up treatment were invited to the study. The ones who were unwilling to participate in the study (n = 15) and/or the ones already taking psychiatric medications (n = 16) were excluded. Finally, 94 patients were enrolled in the study. They were on maintenance immunosuppression with either CNI-based (n = 74) or mTORi-based (n = 20) regimens. As a part of their maintenance immunosuppressive regimens, patients were also receiving prednisolone (5 mg per day) and an antiproliferative agent (mycophenolate at a dosage of 1000-2000 mg per day or azathioprine at a dosage of 50-100 mg per day). All the patients on mTORi-based regimens had been previously on CNI-based regimens, but their therapies were switched to mTORi as a CNI-avoidance strategy due to adverse effects such as nephrotoxicity, hirsutism, and gingival hypertrophy. All of these 20 patients were on mTORibased regimens at least for 6 months. The dosages of CNI (either tacrolimus or cyclosporine (CsA)) and mTORi (either sirolimus or everolimus) were being adjusted according to blood concentrations.
Data collection tools
Sociodemographic features of the patients including age, sex, and marital and employment status were noted based on patients' charts and interviews. The type and time on dialysis before transplantation, transplantation history including donor type, presence of acute rejection episode, time since transplantation, current immunosuppressive medications, and concentrations of serum creatinine at the last visit were recorded. Each patient was assessed by clinical interview and the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI).
Beck Depression Inventory
The BDI is a self-report inventory used to measure the severity of depression. The questionnaire includes 21 multiple-choice items that describe specific depressive symptoms over the past week. Each item is scored on a scale from 0 to 3 and the sum of these gives the total BDI score. Patients having <10 total BDI score are accepted as normal. A total BDI score of ≥10 indicates symptomatic patients, 10-18 indicates mild depression, 19-29 indicates moderate depression, and ≥30 indicates severe depression (11) . The validity and reliability of the BDI in Turkish population were evaluated by Hisli (12).
Beck Anxiety Inventory
The BAI is a self-report inventory developed by Beck et al. (13) to determine the frequency of anxiety symptoms. It is composed of 21 items. Each item is scored on a scale from 0 to 3 and the sum of these gives the total BAI score. Scores of 0-7 were accepted as negative symptomatology for anxiety. Scores of 8-15 show mild, scores of 16-25 show moderate, and scores of 26-63 show severe anxiety (13) .
The reliability and validity of the BAI were established in Turkey (14) .
Statistical analysis
Statistical analysis was conducted using SPSS 18 (SPSS Inc., Chicago, IL, USA). Normality of distribution was tested by the Kolmogorov-Smirnov test and histograms for continuous variables. Normally distributed variables were expressed as mean ± standard deviation and the others are presented as median and interquartile ranges (the range of values lying between the 25th and 75th percentiles). The Student t-test or Mann-Whitney U test was used for comparisons of two groups. Categorical variables were shown as frequency and percentages and were assessed by using the chi-square test or Fisher exact test as appropriate. All P-values were calculated as two-sided, and P < 0.05 was considered as significant.
Results
Demographic characteristics of the participants are presented in Table 1 . The mean age of the patients was 42.84 ± 10.23 years. Of the patients, 74.5% were male, 56.4% were married, and 48.9% were employed.
There was no significant difference between group I (CNI-based regimen, n = 74 patients) and group II (mTORi-based regimen, n = 20) with regard to sex, age, marital status, employment status, dialysis history, or transplantation history. There was a trend toward higher serum creatinine values in group II patients ( Table 1) .
Analysis of the data obtained from the BDI showed that 62 patients (66%) had total scores of ≥10 and were rated as symptomatic for depression; 27 had mild, 21 had moderate, and 14 had severe levels of depression. The mean BDI score was found to be significantly higher in group I compared to group II (P < 0.001). Fifty-six patients (75.6%) had depression (total BDI score of ≥10) in group I (21 patients with mild, 21 with moderate, and 14 with severe depression scores); 6 patients (30%) had depression (total BDI score of ≥10) in group II (all with mild levels of depression scores) (P < 0.001) ( Table 1 ). The prevalence of moderate and severe levels of depression was higher among CNI users (P = 0.015) ( Table 1) .
Analysis of the data collected with the BAI showed that 79 patients (84%) had prominent anxiety symptoms (total BAI score of >7); 31 patients had mild, 26 moderate, and 22 severe levels anxiety. The mean anxiety score was significantly higher in group I than in group II (P < 0.001). However, the prevalence of prominent anxiety symptoms was similar in the two groups (P = 0.299). Sixty-four patients (86.5%) had prominent anxiety (18 patients with mild, 24 with moderate, and 22 with severe anxiety scores) in group I; 15 patients (75.0%) had prominent anxiety (13 patients with mild and 2 with moderate anxiety scores) in group II (Table 1 ). The prevalence of moderate and severe anxiety levels was higher among CNI users (P < 0.001) ( Table 1) .
When the patients on CNI-based regimens were divided into two groups as those on tacrolimus (n = 41) and those on CsA (n = 33), the groups were similar in regard to total BDI and BAI scores, and the prevalence of depression (total BDI score ≥10 ) and anxiety (total BAI score >7). However, the patients on tacrolimus had moderate and severe levels of depression and anxiety symptoms (P < 0.05 for both) ( Table 2 ). When the patients with total BDI score of ≥10 (n = 62) were compared with those with total BDI scores of <10 (n = 32), the age (41.95 ± 9.60 vs. 44.56 ± 11.33, respectively, P = 0. When the patients with prominent anxiety (n = 79) (total BAI score >7) symptoms were compared with those with total BAI scores of <7 (n = 15), the age (43.18 ± 9.93 vs. 41.07 ± 11.94, respectively, P = 0. 
Discussion
In the present study, we observed that the total depression and anxiety scores as well as the severity levels of the diseases were increased in patients on CNI-based regimens compared to those of the patients on mTORi-based regimens. To the best of our knowledge, this is the first study comparing the impacts of CNI-based and mTORibased regimens on depression and anxiety scores and disease severity levels determined by using the BDI and BAI. We found that 66% of our patients had total BDI scores of ≥10 and 84% of them had total BAI scores of >7. These were relatively higher scores compared to the other studies that reported distinctive values for depression ranging from 20% to 75% and for anxiety ranging from 27% to 50% in kidney transplant patients (15) (16) (17) (18) . The types of diagnostic tools, the special characteristics of the study populations (socioeconomic situations, extremely low deceased donor rates, and subsequently longer duration of dialysis treatments in Turkey) could have affected the results. In the medical literature, there have been limited and conflicting results concerning the psychiatric effects of immunosuppressive agents in patients with solid organ transplantation. A small-sized study including nine hearttransplanted cases showed improved mood, memory, and quality of life after switching from CNI-based regimens to everolimus (10) . On the other hand, the psychiatric effects of immunosuppressive agents in kidney recipients were investigated in a single study that yielded impaired attention and memory in sirolimus and tacrolimus users, while cyclosporine users had similar outcomes compared to healthy volunteers (6). In our study, CNI users had significantly increased total BDI and BAI scores as compared to mTORi users. The understanding of the physiological actions of calcineurin and/or mTORi molecules could help in the interpretation of these results. Calcineurin regulates the neurotransmission, neuronal excitability, and plasticity in the amygdala and provides normal mood reactions in human bodies. Some researchers have suggested that it is involved in the regulation of depressive behaviors (19) , and antidepressive agents develop their effects via calcineurin activation (20) . Experimental studies have shown that calcineurin blockage increases depressive-like symptoms (21) and the prevalence of depression and anxiety (22) . Experimental studies showed that mTORi signaling is needed for hippocampus-dependent fear, long-term memory (23) , and the synthesis of brain-derived-neurotrophic factor (BDNF), which is a growth factor secreted from the hippocampus (24, 25) . Recently published data showed alterations of BDNF synthesis in patients with depression (26) and BDNF polymorphism in patients with anxiety (27) . An mTORi, CCI-779, resulted in euphoria followed by melancholia (similar to a temporary bipolar disorder) in one-fifth of patients with malignancy after administration of a single dose (28) . As a consequence, not only calcineurin inhibition but also mTORi inhibition seems to be related with depression and anxiety. The alterations in BDNF and related growth factors in CNI and mTORi users might be subject of further studies.
As general knowledge, tacrolimus more frequently causes psychiatric and neurological symptoms than cyclosporine (29) . However, some authors showed similar results for tacrolimus and cyclosporine (9) , whereas some others showed deteriorated results with tacrolimus (7). In our study, although the frequency and total scores were similar for the BDI and BAI, tacrolimus users were prone to having more severe levels of symptoms.
We observed that marital status was similar between the patients with BDI scores of ≥10 or <10, whereas patients with prominent anxiety symptoms had lower rates of marriage. Sayın et al. noted that marital status did not affect the psychological status of transplanted patients (30) . However, Akman et al. reported a higher incidence of depression in single patients (31) . We thought that family support is important for the mood of the patients. There was a trend towards increased unemployment in patients with BDI scores of ≥10 and a higher rate of unemployment was observed in those with BAI scores of <7. In support of this, a prior study showed that employment affects the prevalence of depression, which appears more frequently in people of low socioeconomic status (32) . These data suggest that unemployment may trigger either depression or anxiety. In our study, the time on dialysis before transplantation was longer in patients with depression and anxiety, in line with the observations of other researchers (33) . The renal replacement modality was hemodialysis in our patients with BDI scores of ≥10, whereas other authors reported no difference in this regard (34) . Similar to Parsei et al. (35) , we showed higher rates of deceased donors in patients with depression and anxiety symptoms. Acute rejection history was significantly higher in patients with depression and anxiety. These findings suggest that fear of rejection may be associated with depressive and anxiety symptoms. One of our patients was retransplanted and had severe levels of depression and anxiety symptoms. A previous study showed a higher incidence of mental disorders in retransplanted patients than in those with a single liver transplantation (36) . Further studies with larger samples are needed to confirm our findings.
Studies have shown that patients who are depressed are less likely to adhere to their medications (37, 38) . A metaanalysis showed that depressed patients were 3-fold more likely to be noncompliant to their medical regimen than patients without depression (37) . The results of another study also suggested that psychological distress such as anxiety and anger may lead to nonadherence to drugs in adolescent renal transplant recipients (38) . Since decreased medication adherence causes organ rejections in transplant recipients, it is very important to diagnose and treat depression in a timely manner. Hence, we suppose that renal transplant recipients should be screened for depression and anxiety regularly and treated appropriately to enhance their quality of life and treatment adherence and to decrease morbidity.
Our study has some limitations. The cross-sectional study design prevents us from establishing an exact cause-and-consequence relation between drug groups and depression and anxiety symptoms. The relatively small number of patients on mTORi-based regimens was a result of the primary choice of CNI-based regimens in maintenance immunotherapy in kidney transplant patients in our center.
In conclusion, we demonstrated increased scores for depression and anxiety by using self-reported inventories in kidney transplant patients, particularly in those on CNIbased regimens. In clinical practice, physicians should also consider the potential adverse effects of CNIs and mTORis on depression and anxiety, besides their more well-known adverse effects. Further studies are warranted to confirm our results and to elucidate the possible underlying mechanisms.
